Evidence-based information about adverse birth outcomes and pregnancy complications is crucial when counseling women with celiac disease (CD); however, limited population-based data on such risks exist. We estimated these for pregnant women with CD diagnosed before and after delivery.
INTRODUCTION
Subclinical pathological evidence of celiac disease (CD) is present in around 1 % of most European populations ( 1 ), of which approximately 0.2 % have been clinically diagnosed with CD ( 2 ) . Th is suggests that about 10 in 1,000 pregnant women could have some form of latent or undetected CD and that about 2 in 1,000 deliveries per year in the United Kingdom will be in women with known CD. Given this estimated prevalence and the potential adverse physiological eff ects that CD might engender, it is surprising that very few good studies have been produced that have tried to quantify the risks to the mother and the child around delivery. Th e studies ( 3 -9 ) that have tried to quantify the risks of pregnancy and delivery-related adverse events among women with CD can be categorized broadly as either case series of individuals, in single or multiple centers pooled together, or registry based. Most case series ( 4, 10, 11 ) have been based on a small number of pregnant women with known CD (i.e., < 150) or pregnant women who are screened for positive serology leading to the identifi cation of a small number of women with previously undiagnosed CD. Unsurprisingly, the results are confl icting; e.g., Martinelli et al. ( 11 ) reported that the 12 pregnant women that they found to have undiagnosed Pregnancy Complications and Adverse Birth Outcomes Among Women With Celiac Disease: A Population-Based S tudy From England CD were more likely to have babies with low birth weight compared with those with negative serology. However, a similar study based on 52 undiagnosed cases from multiple centers found no excess risk of low birth in off springs ( 10 ) . Larger studies from Sweden and Denmark ( 7, 8 ) have used inpatient national registries to identify women with CD, which provide greater number of women but appear to underestimate the prevalence of CD . Th is may explain their fi ndings of an increased risk of some adverse birth outcomes for both mother (cesarean section) and child (low birth weight, intrauterine growth restriction) ( 7, 8 ) if the populations they have studied were not generalizable to all women with CD.
It appears therefore that accurate contemporary estimates of the risk of adverse birth outcomes among women with undiagnosed and diagnosed CD that are generalizable to the majority are absent. Th erefore, we have carried out a population-based cohort study using primary and secondary health-care data from England with the aim of quantifying the risks of pregnancy complications and adverse birth outcomes among women with CD.
METHODS

Study population
We used the Clinical Practice Research Datalink (CPRD) ( 12 ), which is a large longitudinal UK database of computerized primary care (i.e., general practice) records. Th e vast majority of the UK population is registered with general practitioners (GPs), who are responsible for overseeing a patient ' s medical care, which includes coordination of their health care from hospital or other secondary care facilities. Th e CPRD includes practices that have met training standards in their recording of clinical information using Vision soft ware and who have consented to be included in the database ( 13 ) . All patients within a consented practice are automatically included.
Around 53 % of the CPRD practices are linked to Hospital Episode Statistics (HES) ( 14 ) data that contain information on all hospitalizations in England including all discharge diagnoses and procedures. Th e anonymized patient identifi ers from CPRD and HES were linked by a trusted third party using the National Health Service number, date of birth, postcode, and gender ( 15 ) . First, patients were matched exactly according to the National Health Service number (over 90 % of patients are linked in this way), with the remaining patients linked probabilistically on the basis of postcode, date of birth, and gender. As HES only covers English hospitals, practices from Northern Ireland, Wales, and Scotland were excluded. Previously, data from the linked portion of the CPRD have been shown to be broadly representative in terms of age and sex distribution to data from the UK population published by the Offi ce for National Statistics ( 16 ) . We identifi ed all singleton pregnancies recorded in HES between 1997 and 2012 that ended in a live birth or a stillbirth among women aged 15 -44 years as our study population. We therefore had prospectively recorded health and socio-demographic information for women before, during, and aft er pregnancy.
Mothers with CD were defi ned as those with a medical Read code for a diagnosis of CD in their primary care records (Read codes J690.00 CD, J690.13 Gluten enteropathy, J690.14 Spruenontropical, J690100 Acquired CD, and J690z00 CD NOS). We did not include women who had diagnoses of dermatitis herpetiformis (DH); however, women with both diagnoses (CD and DH) were retained in the CD group. Each woman with CD was assigned a date of diagnosis corresponding to the date of her fi rst record of CD or the date of her fi rst prescription of a gluten-free product. Th ese women were then classifi ed as having the CD diagnosis before delivery (diagnosed CD) or aft erward (undiagnosed CD) for each pregnancy in the study. Pregnancies among women with a recorded history of CD before the study start date were included in the diagnosed CD group. Th e method that we used for defi ning CD has been validated in general practice databases with the positive predictive value ranging between 81 and 89 % ( 2 ).
Pregnancies in which women ' s fi rst diagnosis of CD was recorded in the 12 weeks postpartum were also included in the diagnosed CD group. We used this conservative approach to include women who may have had well-controlled CD not requiring medical / GP contact before or during pregnancy but whose postpartum follow-up may have resulted in a recorded diagnosis. Moreover, the diagnostic work-up / process for CD may be long and therefore these are unlikely to be new diagnoses .
Our comparison group consisted of pregnant women without any recorded diagnoses of CD or DH in their primary or secondary care data. Pregnant women who received a gluten-free prescription in the absence of any CD or DH diagnosis at any point during the study period were also excluded.
Defi ning outcomes
We extracted information on pregnancy complications, which included postpartum hemorrhage, antepartum hemorrhage, and pre-eclampsia / eclampsia based on International Classification of Disease version 10 codes from secondary care. Mode of delivery was categorized as normal vaginal delivery, assisted vaginal delivery (forceps, breech, or vacuum), and emergency or elective cesarean section . Information on length of gestation was categorized as normal (37 -42 weeks), preterm ( < 37 weeks), or prolonged ( > 42 weeks), whereas infant ' s birth weight was categorized as normal (2,500 -4,500 g), low birth weight ( < 2,500 g), or macrosomia ( > 4,500 g). We also analyzed birth weight as a continuous variable. Finally, we also extracted information on pregnancies resulting in stillbirths.
Defi ning maternal covariables
For each pregnancy, information on maternal factors during or before pregnancy was extracted from the women ' s medical records. Maternal age at delivery was categorized into six age groups (15 -19, 20 -24, 25 -29, 30 -34, 35 -39 , and 40 -44 years), whereas calendar year was considered in three categories (1997 -2001, 2002 -2007, and 2007 -2012 Health Organization classifi cation), smoking status (the latest measure recorded by the GP before delivery), and ethnicity (as recorded in HES and categorized as white or nonwhite ( 17 )) was also obtained. Socioeconomic status was defi ned as the area in which the general practice was located, at which the patient was registered (quintiles by rank of Indices of Multiple Deprivation ( 18 ) ). Finally pregnant women were defi ned as having diabetes (pre-existing type 1 or type 2) if it was recorded either in primary or secondary care data, or if they had received a prescription for an antidiabetic medication (insulin or oral hypoglycemic agents) any time before delivery.
Statistical analysis
We calculated the proportions of pregnancies with complications or adverse birth outcomes that occurred in women with and without a diagnosis of CD. Th ese proportions were then stratifi ed by the status of the pregnancy with respect to having diagnosed or undiagnosed CD. We used logistic regression to calculate odds ratios (OR) and 95 % confi dence intervals (95 % CI) to assess the associations of CD overall, diagnosed CD, and undiagnosed CD with each pregnancy complication and adverse birth outcome. For categorical outcomes (e.g., mode of delivery), multinomial logistic regression was used and relative risk ratios and corresponding 95 % CIs were calculated. Th ese estimates were adjusted for all potential confounders: maternal age, BMI, smoking status, diabetes, ethnicity, calendar year, and socioeconomic status. Missing information on BMI, smoking status, and birth weight was categorized as a separate category and included in the analysis. We used linear regression to calculate the mean grams of diff erence in the birth weight of infants born to women with CD compared with those born to women without CD while adjusting for all covariables. As some women experienced more than one pregnancy during the study period, a clustering term (in our regression models) was fi tted. For the purpose of this study, we only considered pregnancy complication or adverse birth outcome to be truly associated with CD if we observed an absolute risk diff erence (between women with and without CD) of 3 % or more. All outcomes with the absolute risk diff erence of less than 3 % were considered to be within the random variation of the data.
Sensitivity analyses
We undertook four additional analyses to ensure the robustness of our results. First, we repeated our analysis by restricting the group of women with CD to only those who had received a gluten-free prescription to increase the specifi city of our disease defi nition. Second, we assessed the extent to which women had only hospital recordings of CD using International Classifi cation of Disease version 10 codes (K90.0; with no evidence in their primary care records) and repeated our analysis including these cases. We also repeated our analyses reclassifying those pregnancies in women who had their diagnosis recorded for the fi rst time within the 12 weeks postpartum as undiagnosed CD (rather than diagnosed). Finally, we assessed whether there is an independent increase in the risk of adverse birth outcomes regardless of the mode of delivery.
Th is was done by restricting our analysis to only those women who underwent a normal vaginal delivery. All analyses were carried out using Stata SE version 11.2 (Stata Statistical Software, College Station, TX).
Ethical statement
Th is study was approved by the Independent Scientifi c Advisory Committee reference number = 10_193R.
RESULTS
Study population
Among 276,586 women in our study population, there were 364,186 singleton pregnancies resulting in a live birth or a stillbirth. We excluded 0.07 % ( n = 256) of pregnancies in women with DH without CD (0.01 % ) or who had gluten-free prescriptions without any evidence of concurrent CD (0.05 % ). Th is resulted in a total of 363,930 pregnancies, which were included in the analysis. Th e overall proportion of pregnancies among women with CD was 0.25 % (892 out of 363,930) with the median age at diagnosis of 29 years (inter quartile range = 20.2 -34.7). Of these pregnancies, 62 % ( n = 551) were among women with diagnosed CD and 38 % ( n = 341) among women with undiagnosed CD. Table 1 shows the maternal characteristics for all pregnancies in women with and without CD. Compared with women without CD, women with CD had lower BMI, were less likely to be smokers and had a higher prevalence of diabetes. Pregnant women with diagnosed CD were slightly older than those with undiagnosed CD but otherwise had similar maternal characteristics. Table 2 shows the absolute risks of pregnancy complications and adverse birth outcomes among pregnancies in women with diagnosed and undiagnosed CD and those in women without CD. Overall, pregnancies in women with CD had a slightly higher incidence of postpartum and antepartum hemorrhage, preeclampsia / eclampsia, cesarean section delivery, assisted delivery, stillbirth, preterm birth, and low-birth-weight babies compared with pregnant women without CD (absolute risk difference of < 2.5 % ), all of which were not statistically signifi cant.
Pregnancy complications and adverse birth outcomes among women with CD
Diagnosed CD
Among pregnancies in women diagnosed with CD, we found a slightly higher risk of postpartum hemorrhage with an absolute risk (AR) of 13.2 % ( Table 2 ) than women without CD. Th is corresponded to a 3.5 % excess absolute risk and a 34 % increased adjusted relative risk (OR = 1.34 (95 % CI = 1.04 -1.72)) compared with pregnancies in women without CD ( Table 3 ). Th ere was no statistically signifi cant increased risk of preeclampsia / eclampsia, antepartum hemorrhage, or cesarean section delivery. We observed a greater risk of assisted deliveries among those with diagnosed CD (AR = 15 % vs. 12 % in women without CD), which corresponded to a 34 % increased relative risk (adjusted OR (aOR) = 1.34, 95 % CI = 1.05 -1.71) and a 3 % excess absolute COLON/SMALL BOWEL Abdul Sultan et al.
risk. Th e risk of stillbirth, preterm birth, and babies born with low birth weight was similar among pregnancies in women with diagnosed CD and without CD. Finally, there was no mean diff erence in the birth weight of babies born to women with diagnosed CD compared with women without CD (adjusted mean diff erence = − 15 g; 95 % CI = − 72 g to 41 g).
Undiagnosed CD
Among pregnancies in women with undiagnosed CD, we found no overall increased risk of postpartum hemorrhage, pre-eclampsia / eclampsia, antepartum hemorrhage, or having an assisted delivery or emergency cesarean section ( Tables 2 and 3 ). Compared with pregnancies among women without CD, the risk of preterm birth without CD (aOR = 1.83; 95 % CI = 1.05 -3.17). When we included pregnancies in women with CD who had been classifi ed as diagnosed because of their diagnosis being in the postpartum period as undiagnosed, our risk estimates remained unchanged ( Table 5 ) . Similarly, our estimates for pregnancy complications and adverse birth outcomes remained unchanged when we restricted our analysis to pregnant women who underwent normal vaginal delivery ( Table 5 ). Th is was with the exception of postpartum hemorrhage, which was not associated with increased risk among women with diagnosed CD.
DISCUSSION
Main fi ndings
In this large nationally representative cohort of more than 360,000 singleton pregnancies resulting in a live birth or a stillbirth, we have provided contemporary, generalizable, population-based was roughly similar among those with undiagnosed CD (6.5 % vs. 7.6 % ; aOR = 1.24; 95 % CI = 0.82 -1.88). We found that pregnancies in women with undiagnosed CD resulted in babies with a mean birth weight 65 g lower than babies born to women without CD; however, this diff erence was not statistically signifi cant at the 5 % level (95 % CI = − 151 g to 20 g) aft er adjusting for all potential confounding factors.
Sensitivity and other analyses
Sixty-seven percent of pregnant women with CD received a glutenfree prescription during the study period. Our fi ndings for both diagnosed and undiagnosed CD remained broadly consistent when we added celiac cases recorded solely in the secondary care data ( n = 176) and restricted our analysis to only those cases who received a gluten-free prescription ( n = 595; Table 4 ). However, we did fi nd a statistically signifi cant increased risk of infants with low birth weight born to mothers with CD compared with those estimates of the proportion of pregnancies in England that occur in women either with a diagnosis of CD before delivery or following it and their risk of pregnancy complications and adverse birth outcomes. We found that 0.25 % of pregnancies were among women who had or went on to develop CD, of which over onethird are not diagnosed until aft er delivery. With the exception of postpartum hemorrhage and assisted delivery, we observed no increased risk of pregnancy-associated complications or adverse birth outcomes among the pregnancies in women with diagnosed CD compared with those without the diagnosis. Similarly, we also found that undiagnosed CD is not associated with pregnancy complications and adverse birth outcomes.
Strength and limitations
We have conducted one of the largest studies to determine the risk of pregnancy complications and adverse birth outcomes in CD using data from both primary and secondary care while adjusting for important confounding factors such as BMI, smoking status, and maternal diabetes. Our study used an open cohort approach, with prospectively collected data from across England covering 3 % of the total UK population with a similar age and sex distribution to the population as a whole. Furthermore, HES is the primary source of maternity statistics in England where birth outcomes have been externally validated with high accuracy ( 19 ) . Although our study lacked information on the severity of CD, the use of general practice data to ascertain CD diagnosis makes our study fi ndings not only generalizable to the singleton pregnancies resulting in a live birth or a stillbirth in England but also to other developed nations with similar health-care systems. A weakness of this study is the lack of histological and serological information common to cohorts that have been studied in specifi c secondary or tertiary centers or with complete linkages to pathology systems. However, because the defi nition of CD that we have used is based on recording of a clinical diagnosis by the GPs, it refl ects the real world of clinical practice, as it occurs in the general population of the United Kingdom. Th is, in turn, has allowed us to study a large number of pregnancies, which would not otherwise be easily possible in a bespoke cohort study. Fortunately, this method of defi ning CD has been validated in general practice databases with a positive predictive value ranging between 81 and 89 % , which increases when prescription data are also used ( 2 ). When we increased the specifi city of our diagnosis by restricting our analysis only to cases with a supporting gluten-free prescription, our estimates remained broadly similar for both diagnosed and undiagnosed CD, indicating that any misclassifi cation inherent to our overall defi nition is likely to have had a small eff ect on our estimates. We do acknowledge that CD diagnoses recorded in inpatient data in England have not been validated. For this reason, we only included them in our sensitivity for which our estimates remained unaltered.
It is important to highlight that 33 % of pregnant women with CD diagnosis did not receive gluten-free prescriptions, which may be due to a number of factors. For instance, these prescriptions are expensive and aside from during pregnancy / early postpartum (or if other comorbidities are present) women of this age do not routinely get free prescriptions in England, and hence they may purchase specifi c gluten-free products directly. Moreover, a relatively short duration of follow-up (i.e., our inability to capture those prescriptions) and a high proportion of " prevalent " cases (i.e., women giving up those prescriptions later on aft er diagnosis) may also be contributory factors. Another limitation of this study is the lack of compliance data on a gluten-free diet among those with diagnosed CD. Similar to most studies conducted on the topic, we assumed that all women with diagnosed CD are broadly compliant with a gluten-free diet, which seems reasonable given previous evidence suggesting that complete nonadherence to a gluten-free diet is uncommon among patients with CD ( 20 ) . Th ere could of course be some misclassifi cation in terms of children of mothers with and without CD in our study. It is likely that some mothers without CD in our study may have undiagnosed disease throughout the whole study period. Th is, however, should only bias our results toward the null, i.e., of no increase in the risk of pregnancy complications and adverse birth outcomes.
We also recognize that our lack of complete data on BMI and birth weight could bias our estimates. However, we treated missing data as a separate category and included them in our analysis. Th e fact that we were able to use data on BMI does, however, give us an advantage over other studies ( 3, 7, 8 ) in this fi eld, which have been previously unable to. We observed lower proportions of pregnant women with undiagnosed CD in more recent years compared with those with diagnosed CD. Th is was probably owing to the fact that in order to be undiagnosed a pregnancy needs to occur earlier in the data and vice versa for those with diagnosed CD. It is important to note that our study may have limited power to show small excess risks for certain outcomes (e.g., stillbirths). Th erefore, one cannot rule out minor risk increases associated with these outcomes owing to a potential for type 2 error.
Comparison with previous literature
Th e overall prevalence of CD in our study among pregnant women was calculated to be 0.25 % . Although this proportion is much lower than most small-scale hospital-based studies (1 % ) ( 4, 11 ) , it is not surprising as our cases included those with a clinical diagnosis of CD as opposed to positive serology identifi ed via screening. Our proportions are still higher than those reported by most large registry-based studies (around 0.07 % ) ( 7, 8 ) . Th is may be due to their reliance on inpatient hospital data and lack of outpatient or primary care data leading to the underestimation of the prevalence. We did not observe increased risks of preterm birth and low birth weight among those with diagnosed CD, a fi nding consistent with the available population-based studies ( 3, 7, 8, 11 ) . Our fi nding of a 34 % increased risk of postpartum hemorrhage and assisted deliveries among those with diagnosed CD is new, as previous studies have not reported this.
Overall, we found no increased risk of low birth weight and preterm birth among undiagnosed celiac mothers. Th is fi nding is consistent with a multicenter study conducted by Greco et al. ( 10 ) where 5,055 mothers were screened for CD, of which 51 (1 % ) had a positive result. Th e study concluded that undiagnosed CD, although common in pregnancy, is not associated with an excess risk of preterm delivery, low birth weight, abortion, or intrauterine growth restriction. Our fi ndings do, however, contradict some of the largest registry-based studies to date ( 3, 7, 8 ) . For instance, Ludvigsson et al. ( 7 ) in their population-based study demonstrated that women with undiagnosed CD were 71 % more likely to have preterm birth and over two times more likely to have infants with low birth weight. Th ese diff erent fi ndings to ours could be because the cases identifi ed through hospital-based registers may suff er from a more severe form of disease than those diagnosed within the general population. Our study showed no increased risk of cesarean section in the undiagnosed CD group in contrast to an increased risk among this group in Swedish data ( 7 ) . One explanation could be the diff erence in the medical indication and the incidence of cesarean sections in the United Kingdom and Sweden (26 % ( 21 ) vs. 17 % ( 22 )). Although we did not fi nd an increased risk of stillbirth, we did not assess the risk of earlier fetal losses in our study, and previous studies have indicated that women with CD may have an increased risk of miscarriage ( 9,11 ), which needs further assessment. With regard to overall fertility, although there is mixed evidence as to whether women with unexplained infertility may be more likely to have undiagnosed CD than the general population ( 23, 24 ) , there is evidence ( 9 ) suggesting that women with CD have fertility rates similar to those of the general population. Th e study by Tata et al. ( 9 ) showed no difference in the fertility rate for women with incident vs. prevalent CD, and the prevalence of CD in women who had children was 0.2 % , which was similar to the overall prevalence of the disease in the female population.
Th e only persistently increased risk that we observed was a 34 % increased risk of postpartum hemorrhage and assisted deliveries among those with diagnosed CD, which has not been reported before. Th is may be due to the higher proportion of women undergoing assisted delivery, which may increase the likelihood of postpartum hemorrhage compared with normal vaginal delivery ( 25 ) . Th is increased risk in women with diagnosed CD may therefore be due to more assisted deliveries rather than diseaserelated per se.
Conclusion and implications
Most women with CD diagnosed either before or aft er pregnancy will have a pregnancy and delivery that is not complicated by an adverse event. Our fi ndings do suggest that among women already diagnosed with CD there may be a small increase in the risk of a pregnancy being complicated by a postpartum hemorrhage, but the reasons for this are not entirely clear. Overall, our results should be reassuring to both women and practitioners. However, this study does not preclude that the lack of increased risk observed among pregnant women with CD was due to an adequate treatment of CD before childbirth, thereby optimizing maternal health.
